SCHEMBL2137710

SCHEMBL2137710

CCOC(=O)c1ccc2c(c1)C(C)(C)CC(c1ccccc1N)N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.42
▸ PRMT1 Q99873 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ POLB P06746 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MASP2 O00187 1/20 0.40
▸ GAPDH P04406 1/20 0.40
▸ HSPA1A P0DMV8 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ HSPA8 P11142 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NR4A1 P22736 1/20 0.40
▸ DUSP1 P28562 1/20 0.40
▸ PTPN7 P35236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2138126 0.85 PRKAB2 (0.47) RARARARB
SCHEMBL2142064 0.84 KMT2A (0.44) ARKMT2AALDH1A1POLBMAPT
SCHEMBL2141345 0.83 HPGD (0.42) ARMEN1KMT2AALDH1A1POLB
SCHEMBL2136580 0.81 KMT2A (0.48) ARMEN1KMT2AALDH1A1MAPT
SCHEMBL2137378 0.81 LMNA (0.51) ARMEN1KMT2AALDH1A1POLB
SCHEMBL2136342 0.79 KDM4E (0.43) MEN1KMT2AALDH1A1POLBMAPT
SCHEMBL11025117 0.79 F7 (0.42) ARMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2139850 0.79 F7 (0.33) ALDH1A1POLBMAPTALOX15THRB
SCHEMBL11024600 0.79 F11 (0.45) ARMEN1KMT2AALDH1A1POLB
SCHEMBL11024121 0.79 TP53 (0.44) ARMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630124-B1 TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS HOFFMANN LA ROCHE (CH) 2014-11-19 — — EP disclosed
US-8546427-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2013-10-01 — — US disclosed
EP-2630124-A1 TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS F.HOFFMANN-LA ROCHE AG (CH) 2013-08-28 — — EP disclosed
US-20120101127-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES HUA MEDICINE (KY) 2012-04-26 — — US disclosed
WO-2012052372-A1 TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2012-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101127-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES PRKAG1, PRKAB1, PRKAG2 AR 1588/4885PRMT1 149/4885MEN1 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback